Helus Psychedelic HLP003 Hits Phase 3 Depression Goal, but Serious Adverse Events Draw Scrutiny
Helus Pharma says its deuterated psilocin beat placebo on depression scores at six and 12 weeks in a 222-patient Phase 3 trial. Three treatment-related serious adverse events, including a suicide attempt, have prompted safety questions. The data have not been peer-reviewed.
Safety Questions Mount Over Vykat XR, the First Approved Drug for Hunger in Prader-Willi Syndrome
Prader-Willi syndrome (PWS) is a rare genetic condition, and its best-known feature is a hunger that never switches off. The medical term for that is hyperphagia.